ABSTRACT
Objectives First responders including firefighters, emergency medical technicians (EMT), paramedics, and police officers are working on the front lines to fight the COVID-19 pandemic and facing a higher risk of infection. This study assessed the seroprevalence among first responders in northeastern Ohio during May-September 2020.
Methods A survey and IgG antibody test against SARS-CoV-2 were offered to University Hospitals Health System affiliated first responder departments.
Results A total of 3080 first responders with diverse job assignments from more than 400 fire and police departments participated in the study. Among them, 73 (2.4%) were seropositive while only 0.8% had previously positive RT-PCR results. Asymptomatic infection accounts for 46.6% of seropositivity. By occupation, seropositive rates were highest among administration/support staff (3.8%), followed by paramedics (3.0%), EMTs (2.6%), firefighters (2.2%), and police officers (0.8%). Seroprevalence was not associated with self-reported exposure as work exposure rates were: paramedics 48.2%, firefighters 37.1%, EMTs 32.3%, police officers 7.7%, and administration/support staff 4.4%. Self-reported community exposure was strongly correlated with self-reported work exposure rate rather than seroprevalence suggesting a potential impact of risk awareness. Additionally, no significant difference was found among gender or age groups; however, black Americans have a higher positivity rate than other races although they reported lower exposure.
Conclusions Despite the high work-associated exposure rate to SARS-CoV-2 infection, first responders with different roles demonstrated seroprevalence no higher than their administrative/supportive colleagues, which suggests infection control measures are effective in preventing work-related infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by private donations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the University Hospitals Health System (UHHS) institutional review board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available on request from the authors.
